A descriptive analysis of real-world oncology biosimilar use in Japan

Authors:

Abstract
Aim: To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan.
Funding Information
  • Pfizer Inc

This publication has 35 references indexed in Scilit: